Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New gene therapy SNUG01 enters human trials for ALS

NCT ID NCT07169175

First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 31 times

Summary

This early-stage study tests a new gene therapy, SNUG01, in 21 adults with ALS. The main goal is to see if it is safe and tolerable when given via a spinal injection. Researchers will also look for early signs that it might slow the disease. This is not a cure, but aims to control the disease and improve quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, 350000, China

  • Massachusetts General Hospital

    Boston, Massachusetts, 02467, United States

  • Peking University Third Hospital

    Beijing, Beijing Municipality, 100000, China

  • Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310000, China

Conditions

Explore the condition pages connected to this study.